Cargando…

c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma

BACKGROUND: The immunomodulatory drug lenalidomide, which is now widely used for the treatment of multiple myeloma (MM), exerts pharmacological action through the ubiquitin‐dependent degradation of IKZF1 and subsequent down‐regulation of interferon regulatory factor 4 (IRF4), a critical factor for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osada, Naoki, Kikuchi, Jiro, Iha, Hidekatsu, Yasui, Hiroshi, Ikeda, Sho, Takahashi, Naoto, Furukawa, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426395/ https://www.ncbi.nlm.nih.gov/pubmed/37581569 http://dx.doi.org/10.1002/ctm2.1364

Ejemplares similares

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Lenalidomide induces degradation of IKZF1 and IKZF3
por: Krönke, Jan, et al.
Publicado: (2014)

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
por: Zhou, Nan, et al.
Publicado: (2019)

Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide
por: Abdulkarim, Haya, et al.
Publicado: (2020)

EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress
por: Kikuchi, Jiro, et al.
Publicado: (2022)

Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3
por: Liu, Xiao-Ping, et al.
Publicado: (2018)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
por: Pourabdollah, Maryam, et al.
Publicado: (2016)

C/EBPBeta and Elk-1 synergistically transactivate the c-fos serum response element
por: Hanlon, Mary, et al.
Publicado: (2000)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone
por: Yasui, Taku, et al.
Publicado: (2020)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone
por: Ikeda, Sho, et al.
Publicado: (2019)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system
por: Yamamoto, Naoki, et al.
Publicado: (2022)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma
por: Liu, Meng, et al.
Publicado: (2022)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
por: Moreau, Philippe, et al.
Publicado: (2019)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma
por: Marchetti, Monia, et al.
Publicado: (2021)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Lenalidomide-Induced Diffuse Alveolar Hemorrhage in Patient With Multiple Myeloma
por: Qanash, Sultan, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells
por: Osada, Naoki, et al.
Publicado: (2018)

Expression, mutation, and methylation of cereblon‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
por: Tachita, Takuto, et al.
Publicado: (2020)

Multiple Myeloma–Associated Ig Light Chain Crystalline Cast Nephropathy
por: Matsumura, Hirotoshi, et al.
Publicado: (2020)

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
por: Suzuki, Kenshi, et al.
Publicado: (2016)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?
por: Tailor, Imran K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_inhhhbgjqm6fjtgpfpsgt7u2qq